NeuroVive Pharmaceutical AB Azioni in circolazione
Cos'è Azioni in circolazione di NeuroVive Pharmaceutical AB?
Azioni in circolazione di NeuroVive Pharmaceutical AB è 403.007M
Qual è la definizione di Azioni in circolazione?
Le azioni in circolazione sono tutte le azioni di una società o di un'attività finanziaria che sono state autorizzate, emesse e acquistate dagli investitori e sono detenute da loro.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Azioni in circolazione di aziende nel Health Care settore su OTC rispetto a NeuroVive Pharmaceutical AB
Cosa fa NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Aziende con azioni in circolazione simili a NeuroVive Pharmaceutical AB
- Burberry Plc ha Azioni in circolazione di 402.380M
- ITV Plc ha Azioni in circolazione di 402.541M
- Thermo Fisher Scientific ha Azioni in circolazione di 402.576M
- Brookfield Asset Management Ltd ha Azioni in circolazione di 402.726M
- Triple Point Social Housing Reit Plc ha Azioni in circolazione di 402.789M
- Anacle Systems ha Azioni in circolazione di 402.901M
- NeuroVive Pharmaceutical AB ha Azioni in circolazione di 403.007M
- Aleafia Health Inc ha Azioni in circolazione di 403.039M
- Good Friend International ha Azioni in circolazione di 403.074M
- ZoomInfo Technologies ha Azioni in circolazione di 403.217M
- Allianz SE ha Azioni in circolazione di 403.314M
- Ingersoll-Rand Inc ha Azioni in circolazione di 403.484M
- KB Inc ha Azioni in circolazione di 403.511M